NEW YORK, Oct 6 - PPGx of Morrisville, NC, said Friday that Bristol-Myers Sqibb (NYSE: BMY) has signed on for early access to its GeneTrial software for pharmacogenomics research.
The GeneTrials platform is designed to manage the vast amount of publicly available and in-house clinical and genomic data.
Included in the software package is the GeneTrials Data Warehouse, an Oracle-based repository that uses sophisticated commercial data warehousing technology to integrate, manage, and organize pharmacogenomic data, and the GeneTrials Explorer, a user interface for browsing, querying, annotating, and analyzing information stored within the GeneTrials Data Warehouse.
“As we lead research into the era of personalized medicine, the ability to integrate research data across a variety of disciplines becomes a critical capability,” said Nicholas Dracopoli, executive director of pharmacogenomics at Bristol-Myers Squibb.
Financial terms of the deal were not disclosed.
The agreement, however, underscores the fact that providing shrink-wrapped software might not cut it anymore. PPGx will customize the software for the pharmaceutical company’s specific project needs and will also act as a pharmacogenomics consultant.